Reduced expression of DUSP4 has been identified as an adverse feature in different tumor types and cancer derived cell lines34, 35, 36, 37 and found to be epigenetically silenced in 75% of cases of diffuse B cell lymphoma (DLBCL). Here, DUSP4 is linked to neoplasm.